Cellular Biomedicine Group Inc (NASDAQ:CBMG) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $24.10 and last traded at $23.95, with a volume of 5936 shares trading hands. The stock had previously closed at $21.90.
A number of research analysts recently commented on the company. Zacks Investment Research raised Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a research note on Monday, July 23rd. Maxim Group reaffirmed a “hold” rating on shares of Cellular Biomedicine Group in a research note on Friday, June 15th. Finally, ValuEngine raised Cellular Biomedicine Group from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Cellular Biomedicine Group has an average rating of “Hold” and an average price target of $32.00.
Cellular Biomedicine Group (NASDAQ:CBMG) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.01). Cellular Biomedicine Group had a negative net margin of 10,133.88% and a negative return on equity of 47.52%. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. equities research analysts predict that Cellular Biomedicine Group Inc will post -2.14 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the company. Rhumbline Advisers bought a new stake in shares of Cellular Biomedicine Group in the second quarter worth about $208,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Cellular Biomedicine Group in the second quarter worth about $423,000. Tibra Equities Europe Ltd bought a new stake in shares of Cellular Biomedicine Group in the first quarter worth about $487,000. Northern Trust Corp grew its stake in shares of Cellular Biomedicine Group by 22.9% in the first quarter. Northern Trust Corp now owns 37,980 shares of the biotechnology company’s stock worth $667,000 after purchasing an additional 7,076 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Cellular Biomedicine Group by 208.1% in the second quarter. Bank of New York Mellon Corp now owns 34,579 shares of the biotechnology company’s stock worth $676,000 after purchasing an additional 23,354 shares during the last quarter. 8.31% of the stock is currently owned by hedge funds and other institutional investors.
Cellular Biomedicine Group Company Profile (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.
Further Reading: Leveraged Buyout (LBO)
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.